Cheyne Capital Management (UK)’s Vanda Pharmaceuticals VNDA Stock Holding History

Cheyne Capital Management (UK)’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-41,000	Closed	-$781K	–	43
2018 Q2	$781K	Hold	41,000	–	–	0.56%	31
2018 Q1	$692K	Sell	41,000 -33,000	-45%	-$552K	0.31%	31
2017 Q4	$1.13M	Hold	74,000	–	–	0.49%	32
2017 Q3	$1.32M	Hold	74,000	–	–	0.48%	33
2017 Q2	$1.2M	Hold	74,000	–	–	0.46%	33
2017 Q1	$1.03M	Buy	74,000 +22,000	+42%	+$314K	0.39%	24
2016 Q4	$831K	Hold	52,000	–	–	0.47%	18
2016 Q3	$865K	Hold	52,000	–	–	0.52%	24
2016 Q2	$582K	Hold	52,000	–	–	0.47%	20
2016 Q1	$434K	Buy	52,000 +13,000	+33%	+$107K	0.14%	29
2015 Q4	$363K	Sell	39,000 -70,000	-64%	-$699K	0.2%	29
2015 Q3	$1.23M	Buy	109,000 +70,000	+179%	+$856K	0.58%	25
2015 Q2	$495K	Buy	+39,000	New	+$421K	0.16%	72

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cheyne Capital Management (UK)'s VNDA Position: Q3 2018 in Review

Cheyne Capital Management (UK) sold out of Vanda Pharmaceuticals (VNDA) in Q3 2018, closing a stake of 41,000 shares — an estimated $781K sold.

Cheyne Capital Management (UK) first reported a position in VNDA in Q2 2015 and held it in 13 quarters. The position peaked at $1.32M in Q3 2017. 160 funds tracked by Wall St. Rank hold VNDA as of Q3 2018.

Cheyne Capital Management (UK) reported no remaining Vanda Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Cheyne Capital Management (UK) sold 41,000 Vanda Pharmaceuticals shares in Q3 2018, an estimated $781K.
Cheyne Capital Management (UK) first reported a position in Vanda Pharmaceuticals in Q2 2015 and held it in 13 quarters.
Cheyne Capital Management (UK)'s Vanda Pharmaceuticals position peaked at $1.32M in Q3 2017.
160 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2018.

Based on Cheyne Capital Management (UK)'s 13F filing for Q3 2018, filed 5 Nov 2018.